Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.
For overlap across multiple ETFs use Portfolio Builder
11
Number of overlapping holdings
23.9%
% of IDNA's 51 holdings also in CANC
22.9%
% of CANC's 48 holdings also in IDNA
Overlap by Weight
Sector Drift (IDNA minus CANC)
Overlapping Holdings
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
| Company | Weight in IDNA |
Weight in CANC |
Overlap | |
|---|---|---|---|---|
 |
ASTRAZENECA PLC | 5.1% | 4.2% | 4.2% |
 |
REVOLUTION MEDICINES, INC. | 4.0% | 5.7% | 4.0% |
|
EXELIXIS INC | 5.2% | 3.8% | 3.8% |
|
ARCELLX, INC. | 3.8% | 2.9% | 2.9% |
|
MERCK & CO. INC. | 3.9% | 2.7% | 2.7% |
Position Highlights (Non-Overlapping Exposures)
IDNA Overweight Relative to CANC
 |
BEIGENE, LTD. | 5.8% |
 |
ROCHE HOLDING LTD | 5.5% |
 |
SANOFI-AVENTIS | 5.5% |
|
GSK PLC | 5.3% |
 |
TAKEDA PHARMACEUTICAL CO LTD | 5.2% |
 |
GENMAB A/S | 4.6% |
|
SPRINGWORKS THERAPEUTICS, INC. | 4.3% |
 |
BIONTECH SE SPONSORED ADR | 4.2% |
|
TWIST BIOSCIENCE CORP. | 3.6% |
|
INCYTE CORP | 3.5% |
IDNA Underweight Relative to CANC
|
ELI LILLY & CO | -5.4% |
|
ROCHE HOLDINGS LTD-SPONS ADR | -5.1% |
|
BRIDGEBIO PHARMA, INC. | -4.5% |
|
NOVARTIS AG | -4.3% |
|
BRISTOL-MYERS SQUIBB CO | -4.0% |
|
NUVALENT, INC. CLASS A | -3.9% |
|
SUMMIT THERAPEUTICS INC | -3.9% |
|
GENMAB A/S SPONSORED ADR | -3.4% |
 |
MERUS N.V. | -3.2% |
|
ZAI LAB LTD. UNSPONSORED ADR | -3.0% |